ADI-001 is under clinical development by Adicet Bio and currently in Phase I for Diffuse Large B-Cell Lymphoma. According to GlobalData, Phase I drugs for Diffuse Large B-Cell Lymphoma have a 78% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how ADI-001’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
ADI-001 is under development for the treatment of non-Hodgkin’s lymphomas including follicular lymphoma, mantle-cell lymphoma, marginal zone lymphoma, mediastinal lymphoma, diffuse large b cell lymphoma. The therapeutic candidate comprises of allogenic gamma delta T cells expressing chimeric antigen receptors (CARs) directed to CD20. It acts by targeting cells expressing CD20. It is administered via parenteral route. The therapeutic candidate is being developed based on universal immune cell therapy (uICT) platform technology and T cell receptor-like monoclonal antibodies (TCRLs).
It was under development for the treatment of chronic lymphocytic leukemia (CLL), burkitt lymphoma.
Adicet Bio overview
Adicet Bio, formerly resTORbio, is a clinical stage biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for cancer and other diseases. The company offers gamma delta T cells engineered with chimeric antigen receptors and chimeric adaptors to enhance selective tumor targeting, facilitate innate and adaptive anti-tumor immune response, and enhance persistence for durable activity in patients. Its lead product in pipeline includes ADI-001, which is in Phase I clinical study for the treatment of non-Hodgkin’s lymphoma. The company also develops ADI-002, which is undergoing preclinical studies for the treatment of various solid tumors; and ADI-925, a novel engineered CAd gamma delta T cell product candidate targeting tumor stress ligands. Adicet Bio is headquartered in Boston, Massachusetts, the US.
For a complete picture of ADI-001’s drug-specific PTSR and LoA scores, buy the report here.